Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study)
et al., SSRN Electronic Journal, doi:10.2139/ssrn.3936499, NCT04303299 (history)
, Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and.., SSRN Electronic Journal, doi:10.2139/ssrn.3936499, NCT04303299
RCT 200 moderate/severe patients in Thailand, showing significantly lower progression with favipiravir vs. oseltamivir. NCT04303299 (history).
|
risk of death, 23.1% lower, RR 0.77, p = 0.66, treatment 10 of 100 (10.0%), control 13 of 100 (13.0%), NNT 33, favipiravir arms vs. oseltamivir arms.
|
|
risk of progression, 60.0% lower, RR 0.40, p = 0.009, treatment 10 of 100 (10.0%), control 25 of 100 (25.0%), NNT 6.7, favipiravir arms vs. oseltamivir arms.
|
|
time to viral-, 8.7% lower, relative time 0.91, p = 0.43, treatment mean 9.5 (±5.0) n=50, control mean 10.4 (±6.3) n=50, HCQ arms, primary outcome.
|
|
time to viral-, 8.9% lower, relative time 0.91, p = 0.34, treatment mean 10.2 (±4.6) n=50, control mean 11.2 (±5.7) n=50, non-HCQ arms, primary outcome.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Atipornwanich et al., 5 Oct 2021, Randomized Controlled Trial, Thailand, peer-reviewed, 16 authors, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with lopinavir/ritonavir or duranivir/ritonavir/HCQ) - results of individual treatments may vary, trial NCT04303299 (history).
Abstract: Various combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir,
2
high-dose Oseltamivir, and Hydroxychloroquine for the treatment of Covid-19: A
3
randomized controlled trial. (FIGHT-COVID-19 Study)
4
Kriangsak Atipornwanich, M.D. 1,2, Subsai Kongsaengdao, M.D. 1,2, Piyathida
5
Harnsomburana, M.D. 1,2, Rienthong Nanna, M.D. 3, Chatchawan Chtuparisute, M.D. 3,
6
Piamlarp Saengsayan, M.D.4, Kittima Bangpattanasiri, M.D. 4, Weerawat Manosuthi, M.D.
7
5,
Narumol Sawanpanyalert, M.D. 6, Attasit Srisubat, M.D. 6, Somchai Thanasithichai, M.D.
8
6,
Benchalak Maneeton, M.D. 7, Narong Maneeton, M.D. 7, Chuthamanee Suthisisang, B.
9
Pharm, PhD. 8, Jaturong Pratuangdejkul, B. Pharm, PhD. 8, and Somsak Akksilp, M.D. 2,6
pe
er
re
v
iew
ed
1
10
Affiliations:
11
1
12
of Public Health, Bangkok, Thailand.
13
2
Department of Medicine, College of Medicine, Rangsit University, Bangkok, Thailand.
14
3
Department of Medicine, Monkutwattana Hospital, Bangkok, Thailand.
15
4
Department of Medicine, Central Chest Institute of Thailand, Nonthaburi, Thailand.
16
5
Department of Infectious Disease, Bamrasnaradura Infectious Disease Institute,
17
Nonthaburi, Thailand.
18
6
Department of Medical Services, Ministry of Public Health, Nonthaburi, Thailand.
19
7
Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai,
20
Thailand
21
8
ot
tn
rin
Correspondence: Associate Professor Subsai Kongsaengdao, M.D., Division of
Neurology, Department of Medicine, 2 Rajavithi Hospital (Victory Monument),
Pr
23
Faculty of Pharmacy, Mahidol University, Bangkok Thailand,
ep
22
Department of Medicine, Rajavithi Hospital, Department of Medical Services, Ministry
24
Ratchathewi Road, Bangkok 10400, Thailand, Tel +66 22 062 900 Ext 6120,
25
Fax +66 23 545 477, Email skhongsa@gmail.com
FIGHT COVID-19 study {NCT04303299}
1
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3936499
ABSTRACT
27
BACKGROUND
28
Monotherapy with Remdesivir, Favipiravir, Lopinavir-Ritonavir, or Hydroxychloroquine
29
has been evaluated for the treatment of coronavirus disease 2019 (Covid-19). No
30
antiviral agents have yet been shown to be efficacious in terms of viral clearance and
31
reduction of death in moderate to severe Covid-19 in randomized controlled trials.
32
METHODS
33
We conducted an open-label, randomized, controlled trial of various oral combinations
34
of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, high-dose Oseltamivir, and
35
Hydroxychloroquine in adults who were hospitalized with Covid-19. Ninety patients
36
were randomly assigned to receive either 1) high-dose Oseltamivir and
37
Hydroxychloroquine, 2) Lopinavir-Ritonavir and high-dose Oseltamivir, or 3) Darunavir-
38
Ritonavir, high-dose Oseltamivir, and Hydroxychloroquine, compared to thirty voluntary
39
quarantine patients without antiviral agent for mild Covid-19. In addition, two hundred
40
patients were randomly assigned to receive 1) high-dose Oseltamivir and Lopinavir-
41
Ritonavir, 2) Favipiravir and Lopinavir-Ritonavir, 3) high-dose Oseltamivir and
42
Darunavir-Ritonavir, or 4) Favipiravir and Darunavir-Ritonavir and Hydroxychloroquine
43
for moderate to severe Covid-19.
44
RESULTS
45
A total of 320 patients were enrolled. Those mild Covid-19 patients who received high-
46
dose Oseltamivir and Hydroxychloroquine had a..
Late treatment
is less effective
is less effective
atipornwanich
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.